Title: Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients
with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Version: 3 Date: 15 Oct 2023
Reviewer's report:
i have read the author's response thoroughly and find the revisions don't address the comments
satisfactorily. In my opinion, the comparison is not updated despite the published available data.
skewed data and heterogeneous populations from very limited numbers may provide data that
may not be true.
Title: Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients
with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Version: 3 Date: 15 Oct 2023
Reviewer's report:
i have read the author's response thoroughly and find the revisions don't address the comments
satisfactorily. In my opinion, the comparison is not updated despite the published available data.
skewed data and heterogeneous populations from very limited numbers may provide data that
may not be true.
Please review this paper.
user
Title: Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients
with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Version: 3 Date: 15 Oct 2023
Reviewer's report:
i have read the author's response thoroughly and find the revisions don't address the comments
satisfactorily. In my opinion, the comparison is not updated despite the published available data.
skewed data and heterogeneous populations from very limited numbers may provide data that
may not be true.
assistant